It’s been a busy year for the diabetes technology space, with companies unveiling new technologies, developing products to match their rivals and grappling with regulatory actions that have highlighted quality concerns.

At the beginning of the year, the Food and Drug Administration issued a string of warning letters to Abbott, Beta Bionics and Unomedical over quality issues with continuous glucose monitors and insulin pumps. Dexcom disclosed some CGMs it had discarded were stolen and being resold.

Companies also announced plans for new diabetes devices and aspirations for expanded insurance coverage.

Abbott received a CE mark for a dual glucose-ketone sensor, intended to help people with diabetes avoid a serious complication called diabetic ketoacidosis.

Multiple insulin pump makers, including Insulet and MiniMed, discussed plans to design fully closed loop automated insulin delivery systems, which would allow people to manage their diabetes without meal announcements or bolus insulin doses.

Meanwhile, Tandem Diabetes Care and Beta Bionics announced timelines for tubeless insulin pumps, which would position them to compete with market leader Insulet. 

Here are the top stories from the first half of the year.